纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | Tem7 |
Uniprot No | Q8IUK5 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-500aa |
氨基酸序列 | MRGELWLLVLVLREAARALSPQPGAGHDEGPGSGWAAKGTVRGWNRRARE SPGHVSEPDRTQLSQDLGGGTLAMDTLPDNRTRVVEDNHSYYVSRLYGPS EPHSRELWVDVAEANRSQVKIHTILSNTHRQASRVVLSFDFPFYGHPLRQ ITMATGGFIFMGDVIHRMLTATQYVAPLMANFNPGYSDNSTVVYFDNGTV FVVQWDHVYLQGWEDKGSFTFQAALHHDGRIVFAYKEIPMSVPEISSSQH PVKTGLSDAFMILNPSPDVPESRRRSIFEYHRIELDPSKVTSMSAVEFTP LPTCLQHRSCDACMSSDLTFNCSWCHVLQRCSSGFDRYRQEWMDYGCAQE AEGRMCEDFQDEDHDSASPDTSFSPYDGDLTTTSSSLFIDSLTTEDDTKL NPYAGGDGLQNNLSPKTKGTPVHLGTIVGIVLAVLLVAAIILAGIYINGH PTSNAALFFIERRPHHWPAMKFRSHPDHSTYAEVEPSGHEKEGFMEAEQC |
预测分子量 | 82 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Tem7重组蛋白的虚构参考文献示例(仅供格式参考,非真实文献):
1. **文献名称**:Tem7重组蛋白在肿瘤血管生成中的功能研究
**作者**:St Croix, B. et al.
**摘要**:本研究通过表达并纯化Tem7重组蛋白,证实其与肿瘤血管内皮细胞特异性结合,并通过阻断Tem7信号通路显著抑制小鼠模型中肿瘤血管的形成,提示其作为抗血管生成治疗靶点的潜力。
2. **文献名称**:高效表达Tem7重组蛋白的大肠杆菌系统优化
**作者**:Zhang, L. & Chen, W.
**摘要**:开发了一种基于大肠杆菌的Tem7重组蛋白表达系统,通过密码子优化和纯化工艺改进,获得高纯度蛋白,并验证其与配体相互作用的生物活性,为后续结构研究奠定基础。
3. **文献名称**:Tem7重组蛋白的晶体结构解析及其药物设计应用
**作者**:Smith, J. et al.
**摘要**:利用X射线晶体学解析Tem7重组蛋白的三维结构,揭示其与血管生成素样分子结合的关键结构域,为基于结构的抑制剂设计提供理论依据。
4. **文献名称**:Tem7重组蛋白靶向递送系统在癌症治疗中的评估
**作者**:Wang, Y. et al.
**摘要**:构建了负载化疗药物的Tem7重组蛋白-纳米颗粒复合物,实验显示其可特异性靶向肿瘤血管,显著提高药物在荷瘤小鼠中的疗效并降低全身毒性。
---
注:以上文献为模拟示例,实际研究中请通过PubMed、Web of Science等平台检索真实文献。
**Background of TEM7 (Tumor Endothelial Marker 7) Recombinant Protein**
TEM7. also known as Tumor Endothelial Marker 7. is a transmembrane protein initially identified for its upregulated expression in tumor-associated endothelial cells. It belongs to the TEM family, which includes proteins selectively expressed in vascular endothelial cells during pathological angiogenesis, particularly in cancers. TEM7 is encoded by the *PLXDC1* gene (plexin domain-containing 1) and is implicated in promoting tumor angiogenesis, a critical process for tumor growth and metastasis.
Structurally, TEM7 contains a conserved extracellular plexin-like domain, which may mediate interactions with extracellular ligands or other cell surface receptors. Its expression is tightly regulated by hypoxia and oncogenic signaling pathways, such as VEGF and HIF-1α, linking it to the tumor microenvironment’s demands for blood supply. Studies suggest TEM7 facilitates endothelial cell migration, adhesion, and tubule formation, supporting neovascularization in tumors.
Recombinant TEM7 protein is produced using expression systems like *E. coli* or mammalian cells, enabling researchers to study its biochemical properties and interactions. Purified TEM7 is utilized in binding assays, antibody development, and functional studies to explore its role in angiogenesis and cancer progression. Notably, TEM7 is considered a potential therapeutic target; inhibitors or antibodies against TEM7 could disrupt tumor vasculature, enhancing chemotherapy efficacy.
Despite progress, TEM7’s exact molecular mechanisms and ligands remain partially unresolved. Ongoing research aims to clarify its signaling pathways and validate its diagnostic or prognostic value in cancers. Recombinant TEM7 protein serves as a vital tool in these investigations, bridging gaps in understanding tumor biology and anti-angiogenic therapy development.
×